Released Nov 12, 2026, before the open
10-Q filed Nov 12, 2026, 43 days after period end · 0001372514-26-000092
Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today reported financial results for the third quarter ended September 30, 2026, and provided a business update highlighted by the in-licensing of KIO-401, a late-stage, oral neuroprotective calpain inhibitor.
The release| Metric | Q3 2026 | Q3 2025 | Q3 2024 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.00M | $0.00 | $0.00 | $0.00 |
| Net Income | -$1.75M | $26.81K |
Kiora Pharmaceuticals Inc · CIK 1372514 · Engraved from SEC EDGAR
| -$3.41M |
| -$5.76M |
| EPS Diluted | -$0.28 | $0.01 | -$0.81 | -$7.30 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kiora reported a net loss of approximately $1.7 million, or $0.28 per basic and diluted share, for the third quarter of 2026, compared with net income of approximately $27,000, or $0.01 per share, for the third quarter of 2025.¶2
Kiora in-licensed exclusive development and commercialization rights outside Asia to KIO-401 (mitucapistat) from Senju Pharmaceutical Co., Ltd.¶3
Collaboration revenue was $1.0 million for the third quarter of 2026 related to the KIO-301 agreement with CKD, with no comparable revenue recognized in the third quarter of 2025.¶4
Kiora ended the third quarter with approximately $16.3 million in cash and short-term investments, compared with $17.1 million as of December 31, 2025.¶5
Research and development expenses were approximately $1.9 million for the third quarter of 2026, compared with $2.7 million for the third quarter of 2025.¶6